From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Commissioner **US** Department of Commerce United States Patent and Trademark Office, PCT 2011 South Clark Place Room CP2/5C24 Arlington, VA 22202 **ETATS-UNIS D'AMERIQUE**

Date of mailing (day/month/year)

08 January 2001 (08.01.01)	in its capacity as elected Office		
International application No. PCT/GB00/01589	Applicant's or agent's file reference		
International filing date (day/month/year) 25 April 2000 (25.04.00)	Priority date (day/month/year) 23 April 1999 (23.04.99)		
Applicant			
WILKINSON, John, Alfred			

X	in the demand filed with the International Preliminary Examining Authority on:
	23 November 2000 (23.11.00)
	in a notice effecting later election filed with the International Bureau on:
The e	election X was
	was not
made Rule	e before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland


Authorized officer

Jean-Marc Vivet

Facsimile No.: (41-22) 740.14.35 Telephone No.: (41-22) 338.83.38

TENT COOPERATION TRI





INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

SC7/527	45/001	FOR FURTHER ACTIO	A.I	y Examination Report (Form PCT/IPEA/416)	
Internation	al application No.	International filing date (day/n	onth/year)	Priority date (day/month/year)	
PCT/GB	PCT/GB00/01589 25/04/2000 23/04/1999				
Internation A01N65/	al Patent Classification (IPC) or na	tional classification and IPC			
Applicant		<u> </u>	·		
WILKINS	SON;JOHN ALFRED				
1. This i	nternational preliminary exami s transmitted to the applicant a	nation report has been prep ccording to Article 36.	ared by this Inte	ernational Preliminary Examining Authority	
2. This f	REPORT consists of a total of	12 sheets, including this co	er sheet.		
b	his report is also accompanied een amended and are the bas see Rule 70.16 and Section 60	is for this report and/or shee	ts containing re	on, claims and/or drawings which have ectifications made before this Authority ne PCT).	
These	annexes consist of a total of	9 sheets.			
3. This r	eport contains indications relat	ting to the following items:			
ı	Basis of the report				
.11					
Ш	☑ Non-establishment of or	pinion with regard to novelty,	inventive step	and industrial applicability	
IV	☑ Lack of unity of inventio	n			
V	V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement				
VI	⊠ Certain documents cite				
VII	Certain defects in the in	ternational application			
VIII	☑ Certain observations on	the international application			
Date of sub	mission of the demand	Date	of completion of	this report	
23/11/200	00	01.0	8.2001		
Name and n	nailing address of the international	Auth	orized officer		

Klaver, J

Telephone No. +49 89 2399 8601

European Patent Office D-80298 Munich

Fax: +49 89 2399 - 4465

Tel. +49 89 2399 - 0 Tx: 523656 epmu d

preliminary examining authority:

Applicant's or agent's file reference

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/01589

I.	Bas	sis of the report		
1.	the and	receiving Office in	response to an invitation under	ation (Replacement sheets which have been furnished to Article 14 are referred to in this report as "originally filed" ontain amendments (Rules 70.16 and 70.17)):
	1-2	9	as originally filed	
	Cla	ims, No.:		
	1-6	0	with telefax of	16/07/2001
	Dra	wings, sheets:		
	1/10	0-10/10	as originally filed	
2.				above were available or furnished to this Authority in the d, unless otherwise indicated under this item.
	The	se elements were a	available or furnished to this Aut	nority in the following language: , which is:
		the language of a t	translation furnished for the purp	poses of the international search (under Rule 23.1(b)).
		the language of pu	iblication of the international app	olication (under Rule 48.3(b)).
		the language of a t 55.2 and/or 55.3).	translation furnished for the purp	oses of international preliminary examination (under Rule
3.	With inte	n regard to any nuc rnational preliminan	leotide and/or amino acid seq y examination was carried out o	uence disclosed in the international application, the n the basis of the sequence listing:
		contained in the int	ternational application in written	form.
		filed together with t	the international application in c	omputer readable form.
		furnished subseque	ently to this Authority in written t	orm.
		furnished subseque	ently to this Authority in comput	er readable form.
		The statement that the international ap	t the subsequently furnished wri oplication as filed has been furni	tten sequence listing does not go beyond the disclosure in shed.
		The statement that	the information recorded in cor	nputer readable form is identical to the written sequence

☐ the description,

☐ the claims,

Histing has been furnished.

4. The amendments have resulted in the cancellation of:

pages:

Nos.:

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/01589

		the drawings,	sheets:
5.	☒		established as if (some of) the amendments had not been made, since they have been cond the disclosure as filed (Rule 70.2(c)):
		(Any replacement sh report.) see separate sheet	eet containing such amendments must be referred to under item 1 and annexed to this
6.	Add	litional observations, i	f necessary:
HI.	Nor	n-establishment of o	pinion with regard to novelty, inventive step and industrial applicability
1.			e claimed invention appears to be novel, to involve an inventive step (to be non- ally applicable have not been examined in respect of:
		the entire internationa	al application.
	☒	claims Nos. 20-32, 3	5 - 37.
be	caus	e:	
			application, or the said claims Nos. relate to the following subject matter which does ational preliminary examination (<i>specify</i>):
			s or drawings (<i>indicate particular elements below</i>) or said claims Nos. are so unclear binion could be formed (<i>specify</i>):
		the claims, or said cla	aims Nos. are so inadequately supported by the description that no meaningful opinion
	×	no international searc	ch report has been established for the said claims Nos. 20-32,35-37.
2.	and/		I preliminary examination cannot be carried out due to the failure of the nucleotide ice listing to comply with the standard provided for in Annex C of the Administrative
		the written form has r	not been furnished or does not comply with the standard.
		the computer readabl	e form has not been furnished or does not comply with the standard.
٧.	Lac	k of unity of inventio	n
1.	In re	sponse to the invitation	on to restrict or pay additional fees the applicant has:
		restricted the claims.	

International application No. PCT/GB00/01589

		paid additional fees.			
		paid additional fees und	der prote	est.	
		neither restricted nor pa	aid addi	tional fee	s.
2.	×	This Authority found tha 68.1, not to invite the ap	at the re oplicant	quiremen to restric	nt of unity of invention is not complied and chose, according to Rule t or pay additional fees.
3.	This	s Authority considers tha	t the red	quirement	t of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 i
		complied with.			
	×	not complied with for th	e follow	ing reaso	ns:
4.		sequently, the following mination in establishing			national application were the subject of international preliminary
		all parts.			
	×	the parts relating to clai	ms Nos	. 1 - 19, 3	33 (partly), 34 (partly), 38 - 60.
V.		soned statement unde tions and explanations			ith regard to novelty, inventive step or industrial applicability;
1.	Stat	ement			
	Nov	elty (N)	Yes: No:	Claims Claims	6,7,9-19,38-40,44-53,56,58,60 1-5,8,33,34,41-43,54,55,57,59
	Inve	entive step (IS)	Yes: No:	Claims Claims	1-19, 33-57,60 (all insofar as novel) 58
	Indu	strial applicability (IA)	Yes: No:	Claims Claims	1-18, 33-47,49-60
2.	Cita	tions and explanations			

VI. Certain documents cited

see separate sheet

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

International application No. PCT/GB00/01589

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted: see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made: see separate sheet

Item I. 5. Amendments

Amended claims 38 and 41 are directed at a composition comprising a particular essential oil in a gel carrier galanthamine for use as a medicament for topical administration. Original claim 38 was not restricted to a therapeutical use, but insofar as such a use has been disclosed in the application as filed, it concerns the treatment of parasitic insect infestations on humans or animals. Original claim 40 was directed at a (galanthamine) composition for use in the treatment of a human or animal having a parasitic insect infestation.

There is thus no basis in the application documents as originally filed for further medical or therapeutic effects of topically applied gel based essential oil formulations or galanthamine compositions. The amendments of claims 38 and 41 hence go beyond the disclosure of the application as filed, contrary to Rule 70.2 (c) PCT.

Item IV. Lack of unity

The International Examining Authority agrees with the Searching Authority on its finding that the application does not comply with the requirement of unity of invention.

The International Search Report (ISR) has been established for the following (groups of) inventions, which are not linked together by a novel common inventive concept:

i. Claims 1 - 19, 33 (partly), 34 (partly)

- A pharmaceutical composition for use in the treatment of a human or animal having a parasitic insect infestation comprising an essential oil obtained from a plant selected from the genera Artemisia, Citrus, Juniperus, Laurus, Myristica, Origanum, Piper or Aloysia in a gel carrier.
- Use of a gel and essential oil as defined above in the manufacture of a pharmaceutical composition for the treatment of a human or animal having a parasitic insect infestation.
- A method of treating a human or animal suffering from a parasitic insect infestation by applying a composition as defined here above.

ii. Claims 38, 39, 40, 53 (partly)

- Composition comprising an essential oil obtained from a plant selected from the genera Pelargonium, Cymbopogon, Pimpinella, Myrtus (Cretian, Moroccan, organe), Lavandula, Pinus, Melaleuca, Cinnamomum, Apium, Thymus, Hyssopus, Rosemarinus, Cananga, Mentha, Eucalyptus or Vitex in a gel carrier for use as a medicament for topical administration.
- Use of a gel and an essential oil as defined above in the manufacture of a composition

EXAMINATION REPORT - SEPARATE SHEET

as defined above for the treatment of a human or animal having a parasitic insect infestation.

- Method for killing particular parasitic insects by applying this composition.

iii. Claims 41 - 52, 53 (partly)

- Composition comprising the alkaloid galanthamine for use as a medicament for topical administration.
- Use of galanthamine or an extract of Narcissus in the manufacture of a composition for treating a human or animal suffering from a parasitic insect infestation.
- Method of treating a human or animal suffering from a parasitic insect infestation by applying the composition defined here above.
- Method suitable for treating furnishing, clothing or plants to kill parasitic insects by applying the composition defined here above.

Method of killing particular parasitic insects by application of the compositions defined above.

iv. Claims 54 - 60

- Use of a gel carrier and one or more of various specified terpenes and terpenoids shown to have insecticidal activity for the preparation of a medicament for treating humans or animals having a parasitic insect infestation suitable for topical administration.
- Use of one or more of the specified terpenes or terpenoids at a concentration of 4% by wt. or above for the preparation of a medicament for treating humans or animals having a parasitic insect infestation.

Method suitable for treating clothing, furnishing or plants to kill parasitic insects by exposing the substrates to a gel carrier and one or more of the terpenes or terpenoids defined above.

The inventions numbered i. - iv. are not so linked as to form a single general inventive concept (Rule 13.1 PCT) for the following reasons:

The common feature linking together the inventions numbered i., ii. and iv. is the parasiticidal (in particular pediculicidal) effect of essential oils or certain ingredients thereof. This effect is known from the prior art (see, inter alia, CH 688 787 A5, WO 96/14046 A1, JP 10 120 519 A and WO96/37210 A1 (example 4) for essential oils as mentioned in claims 1 or 38 and US 4,933,371 for a terpenoid of claim 54).

Compositions comprising an essential oil derived from genera as defined in claim 1 for use in a first medical treatment furthermore also are known in the art as can be seen from, inter alia, WO 96/37210 A2. The 'medical-use' feature in independent claims 1, 20, 22, 33 and 54 hence cannot be used as a unifying feature for the claimed compositions.

Moreover, invention Nr. ii. defines essential oils obtained from other plant genera than the ones defined in claims 1, 20 or 22. For this reason alone, this invention is not linked by a common general inventive concept to the invention Nr. i. either.

The alkaloid galanthamine is not considered an essential oil and the compositions/use or methods as defined by claims 40 - 51 and 52 (partly) (invention Nr. iii.) hence are not linked by a common general inventive concept to the compositions or methods of the other claims.

The compositions used in invention Nr. iv. may contain a range of terpenes or terpenoids, all of which are known to possess insecticidal or miticidal activity. See for example US 4,933,371 and the last 5 documents cited in the ISR.

The gel-formulation is not a unifying novel feature, since invention Nr. iii. is not restricted to gel formulations and, moreover, gels comprising essential oils are known from the prior art (WO 95/23815 A1, CH 688 787 A5, EP 495 684 A1 and WO 94/09631). The medical (topical) use indication of (some of) the claimed gels is not considered sufficient as a unifying inventive concept for inventions Nrs. i., ii. and iv. since method-claims 53, 59 and 60 are directed at non-medical uses and therapeutic gels comprising active ingredients as dëfined by claim 54 are known from (e.g.) WO 94/09631 A1.

Item V. Novelty, inventive step and industrial applicability.

For the assessment of the present claims 19 and 48 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Invention Nr. i (claims 1 - 19, 33 (partly), 34 (partly))

a). Claims 1 - 5 and 8 are not novel within the meaning of Art. 33 (2) PCT for the following reason:

WO 95/23815 A1 (= D12) discloses in example 9 a (pharmaceutical) composition comprising about 3% of an essential oil obtained from Juniperus in an agar based gel carrier which is effective in the treatment of acne. Since acne normally is considered a skin disease, said composition anticipates the pharmaceutical compositions of claims 1 - 5. 8 33 and 34, at least insofar as the active ingredient derives from Juniperus.

b). Pharmaceutical compositions as defined by present claim 1 for use in the treatment of humans or animals having a lice infestation comprising gels with essential oils obtained from plants other than Juniperus have not been disclosed in the available prior art.

JP 63 260 956 A (= D10) discloses fragrant gels and WO 97/17944 A1 (= D11) discloses agar based gels for cosmetic applications.

CH 688 787 A5 (= D1) and EP 495 684 A1 (= D4) disclose, that essential oil comprising gels may be used as an alternative for antiparasitic shampoos. D4 moreover only discloses a lice-repellent effect, which is less for gels than for a spray (D4: page 9, line 15 - 18).

Example 1a of the application discloses, that gel-based formulations of sage oil have a much lower LD₅₀ value than isopropylalcohol/water based formulations.

It follows from Figures 3 and 4, that it is plausible to expect an analogous enhanced pediculicidal effect of gels comprising other essential oils.

Such an advantageous effect of gel based formulations of essential oils of claim 1 is not derivable from the available prior art

The subject-matter of claims 1 - 19, 33 and 34 (the latter insofar as dependent on claims 1 - 17), insofar as clearly and unequivocally distinguished from D12, hence is novel and based on an inventive step (Art. 33 (2) and (3) PCT).

Invention Nr. ii (claims 38 -40, 53 (partly))

a). Insofar as the compositions of claim 38 and 39 are directed at the topical application as a medicament for treatment of humans or animals having a parasitic infestation, they are novel with respect to the prior art since none of the citations of the International Search Report disclose gels comprising essential oils as defined by claim 38 for such a therapeutic use. The only document disclosing such gels for therapeutically controlling parasite infestation is WO 97/47193 A1 (= D13). The gels used in this document, however, are slow release formulations for use in a bee hive and are not intended for topical use on humans or animals.

D1 discloses the antiparasitic effect of (topically applied) essential oils and mentions gels



as a possible formulation without giving a specific example of such a formulation.

WO 96/37210 A2 (= D9) discloses pharmaceutical compositions comprising essential oils for topical use, but does not disclose gels.

The subject-matter of claims 38 - 40 hence is novel with respect to the prior art (Art. 33 (2) PCT).

The subject-matter of claim 53 ((non-therapeutic) method of killing specified parasitic insects by using the gels of claims 38 and 39) also is novel over the prior art. See, however, item VIII below.

b). The inventive step underlying the claims can be accepted for essentially the same reasons as given above for invention Nr. i.

Claims 38 - 40 and 53 hence also meet the criterion set forth in Art. 33 (3) PCT.

Invention Nr. iii (claims 41 - 52, 53 (partly))

a). Compositions comprising galanthamine for use as a medicament for topical administration as defined by claims 41 - 43 are anticipated by the therapeutic galanthamine formulations of US 5,519,017 (= D17) and WO 96/29332 A1 (= D18). Said documents disclose therapeutic galanthamine compositions for transdermal delivery or for use as an eye ointment which both are within the scope of the term 'for topical administration'.

Claims 41 - 43 hence are not novel (Art. 33 (2) PCT).

Incorporation of the feature 'for treatment of a human or animal suffering from a parasitic insect infestation' into these claims would render the claimed compositions novel with respect to D17 and D18 since such a treatment does not require transdermal delivery of the active ingredient.

b). Gels comprising galanthamine or compositions comprising 0.1 - 20% alcohol have not been disclosed in the available prior art. The subject-matter of claim 44 - 46 hence is novel.

The subject-matter of claims 47 - 53 (the latter insofar as dependent on claims 41 - 46) also is novel over the prior art, since none of the documents D17, D18 or Numata et al. (= D16) disclose a parasiticidal (pediculicidal) effect of galanthamine.

c). D16 discloses the potent antifeeding and insecticidal activity of galanthamine against



INTERNATIONAL PRELIMINARY EXAMINATION REPORT - SEPARATE SHEET

larvae of the yellow butterfly. A parasiticidal (pediculicidal) effect of galanthamine as demonstrated in example 5 of the application has not been disclosed or suggested in this document or in any other citation of the ISR.

The subject-matter of claims 44 - 53 (insofar as dependent on claims 41 - 46) hence is considered to be based on an inventive step (Art. 33 (3) PCT).

Invention Nr. iv (claims 54 - 60)

a). US 4,379,168 (= D22) discloses gels comprising limonene used for the topical treatment of animals suffering from insect (lice) infestation: see D22, col. 6, line 66 - col. 7, line 4.

D22 hence anticipates the novelty of claims 54, 55 and 57.

The addition of further terpenes or terpenoids to such compositions in order to enhance their efficacy is obvious in view of US 4,933,371 (D5). Claims 58 hence is not inventive.

JP 4 139 104 A (= D20) discloses gels comprising terpenes such as sabinene, limonene, camphor etc. for use against household mites and anticipates the novelty of the method as defined by claim 59.

- b). Since none of the citations of the ISR disclose the use of gels comprising terpenes or terpenoids other than limonene for the topical treatment of humans or animals suffering from parasitic insect infestation, claims 54 58 are novel for these embodiments. Method for treating plants using such gels have not been disclosed in the available prior art. Claim 60 hence is novel.
- c). Claims 54 58 and 60, insofar as novel, are considered inventive (Art. 33 (3) PCT), since it can be seen from Fig. 7 9 and Example 2a, that gel based formulations have a much stronger parasiticidal effect than the oil based formulations of the same active ingredients. Such an effect is not derivable from the available prior art.

Item VI Certain documents cited

The following documents were published after the priority date of 23.04.99 GB as claimed by the present application: WO 00/00213 A1 (= D2) (publication date: 06.01.00), WO 99/37148 A1 (= D6) (PD: 29.07.99) and GB 2 341 091 A (= D7) (PD: 08.03.00).

The priority document is silent on gel based formulations or the use thereof. The priority hence only has been validly claimed for the subject-matter of claims 20 - 32, 33 and 34

(both insofar as dependent on claims 20 - 32), 35 - 37, 41 - 43 and 47 - 53 insofar as these claims do not relate to gel based formulations or the use thereof.

D2, D6 and D7 thus do not form part of the prior art of these parts of the application (Rule 64.1 (b) (ii) PCT) but are compressed in the prior art of all other claims, including all gelbased embodiments.

D2 discloses compositions for the treatment of head lice comprising 0,5 - 50% of an essential oil in a carrier fluid such as an alcohol or a non-essential oil. D2 does not disclose compositions based on gel carriers.

D6 discloses pharmaceutical formulations for the treatment of lice or lice eggs comprising one or more terpenes in an aqueous carrier. D6 does not disclose gel based carriers.

D7 discloses a method for the treatment of head lice using shampoo formulations comprising particular essential oil combinations. D7 does not disclose gel based formulations.

Item VII. Certain defects

- Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1, D3, D5, D9 and D17 is not mentioned in the description, nor are these documents identified therein.
- The reference in Example 5 ('M. Ryan') is incomplete.

Item VIII. Clarity

The following objections are raised pursuant to Art. 6 PCT:

- The term 'carbomer' in claim 7 is ambiguous. it is not clear to which compound or class of compounds this term refers. In case the same gelling agent as is used in the compositions of D4 is intended, this term cannot be used in the claim since it refers to a trade mark which may only be used if they are generally recognized as having a precise meaning (Guidelines PCT Ch. III §4.5b (March 1993)).
- Various embodiments of the claims are not present in the description (claims 7 and claims 13 - 17), resulting in doubts regarding the intended scope of protection.
- The intended scope of claims 38, 39 and 41 46 is obscured by the fact, that (nontherapeutic, non-medical) method claim 53 uses the same (medical/therapeutic) formulations as defined by said claims 38, 39 and 41 - 46.

P.10/18

-30-

CLAIMS:

5

10

30

- 1. A pharmaceutical composition comprising an essential oil in a gel carrier, said essential oil being obtained from a plant selected from the genera Salvia, Artemisia, Citrus, Juniperus, Laurus, Myristica, Origanum, Piper or Aloysia, said composition being for use in the treatment of a human or animal having a parasitic insect infestation.
- 2. A composition as claimed in claim 1 wherein the concentration of essential oil is from about 0.1 to about 50% w/v of the composition.
- 3. A composition as claimed in claim 2 wherein the concentration of essential oil is from about 0.1 to about 8% w/v of the composition.
- 4. A composition as claimed in claim 3 wherein the concentration of essential oil is about 4% w/v of the composition.
- 5. A composition as claimed in any preceding claim wherein the gel is based on agar, agarose,25 gelatin or a synthetic gelling agent.
 - 6. A composition as claimed in claim 5 wherein the synthetic gelling agent is a gel based on glyceryl polymethacrylate and propylene glycol.
 - 7. A composition as claimed in claim 4 or claim 5 wherein the gel is a carbomer.
- 8. A composition as claimed in any one of claims
 5 to 7 wherein the gelling agent contains about 0.1 to
 about 95%, preferably about 0.1 to about 66% water v/v
 and/or alcohol, preferably isopropyl alcohol (IPA) at

. . . 10 /07 /0001 17 . 40

5

10

25

35

-31-

about 0.1% to about 20% v/v.

- 9. A composition as claimed in any preceding claim wherein said essential oil is obtained from Salvia lavandulifolia or Salvia officinalis.
- 10. A composition as claimed in any one of claims 1 to 8 wherein said essential oil is obtained from a plant of the genera Citrus.
- 11. A composition as claimed in any one of claims 1 to 8 which includes essential oil obtained from the plant genera Salvia and Citrus.
- 12. A composition as claimed in claim 9 which comprises the essential oil of Salvia lavandulifolia at about 4% w/v dispersed in a gel diluted about 1:2 v/v with water.
- 20 13. A composition as claimed in any preceding claim comprising an anti-pruritic agent.
 - 14. A composition as claimed in claim 13 wherein said anti-pruritic agent is Aloe vera.
 - 15. A composition as claimed in claim 14 wherein said composition includes Aloe vera gel.
- 16. A composition as claimed in claim 15 which comprises about 0.1 to about 5.0% w/v Aloe vera gel.
 - 17. A composition as claimed in any one of claims 12 to 16 which comprises about 0.5% w/v Aloe vera gel.
 - 18. Use of a gel and essential oil selected from the essential oils defined in claim 1 in the

P.12/18

-32-

manufacture of a composition as claimed in any one of claims 1 to 17 for the treatment of a human or animal having a parasitic insect infestation.

- 5 19. A method of treating a human or animal suffering from a parasitic insect infestation comprising applying to said human or animal a composition as claimed in any one of claims 1 to 17.
- 20. A composition comprising an essential oil in an aqueous alcoholic vehicle wherein said vehicle comprises from about 0.1% up to about 20% alcohol v/v with water and wherein said essential oil is obtained from a plant selected from the genera Salvia,

 Artemisia, Citrus, Juniperus, Laurus, Myristica, Origanum, Piper or Aloysia, said composition being for
- 20 21. A composition as claimed in claim 20 wherein said vehicle comprises about 20% v/v alcohol with

parasitic insect infestation.

water.

use in the treatment of a human or animal having a

- 22. A composition comprising an essential oil in a vehicle comprising an alcohol/vegetable oil mixture wherein said alcohol is present in said vehicle in an amount of about 0.1% up to about 20% v/v and wherein said essential oil is obtained from a plant selected from the genera Salvia, Artemisia, Citrus, Juniperus, Laurus, Myristica, Origanum, Piper or Aloysia said composition being for use in the treatment of an animal having a parasitic insect infestation.
- 23. A composition as claimed in claim 22 wherein said vehicle comprises about 20% alcohol v/v.

· -33-

- 24. A composition as claimed in any one of claims 20 to 23 wherein the alcohol is isopropyl alcohol.
- 5 25. A composition as claimed in any one of claims 20 to 24 wherein said essential oil is obtained from Salvia lavandulifolia or Salvia officinalis.
- 26. A composition as claimed in any one of claims 20 to 24 wherein said essential oil is obtianed from a plant of the genera Citrus.
- 27. A composition as claimed in any one of claims 20 to 24 wherein said essential oil is obtained from the genera Salvia and Citrus.
 - 28. A composition as claimed in any one of claims 20 to 27 which is formulated as a dip, spray or pour-on treatment.
 - 29. Use of an aqueous alcoholic vehicle and an essential oil as defined in claim 20 in the manufacture of a composition for the treatment of a human or animal having a parasitic insect infestation.
 - 30. A method of treating a human or animal suffering from a parasitic insect infestation comprising applying to said human or animal a composition as claimed in any one of claims 20, 21, 24, 25, 26, 27 and 28.
 - 31. Use of a vegetable oil/alcohol vehicle and an essential oil as claimed in claim 22 in the manufacture of a medicament for the treatment of an animal having a parasitic insect infestation.

20

25

30

35

P.14/18

-34-

32. A method of treating an animal having a parasitic insect infestation comprising applying to said animal a composition as claimed in any of claims 22 to 28.

5

33. A composition for use as claimed in any one of claims 1 to 17 and 20 to 28 wherein said parasitic insects are selected from lice, lice eggs, mites, fleas or parasites associated with blowfly strike.

10

15

20

25

30

35

- 34. A composition as claimed in claim 33 wherein said parasitic insects are selected from head lice (Pediculus humanus capitis, syn. P. capitis), clothing lice (Pediculus humanus humanus syn. P. corporis), pubic lice (Pthirius pubis), biting lice (Bovicula ovis), scab mite (Psoroptes ovis), ear mite (Psoroptes cuniculi), dust mites (primairly of the genus Dermatophagoides, pig mites, cat fleas (Ctenocephalalides felis), dog fleas (C. canis), horse fleas and Lucilia or Chrysomya species.
- 35. A method suitable for treating furnishing or clothing to kill parasitic insects which comprises exposing said furnishings to a composition of the type defined in any one of claims 20, 21, 24, 25, 26, 27 and 29.
- 36. A method suitable for treating plants to kill parasitic insects which comprises applying to said plants a composition of the type defined in any one of claims 20, 21, 24, 25, 26, 27 and 29.
 - 37. A method as claimed in claim 36 wherein said parasitic insects are selected from the genera Aphis, Chilo, Dysderus, Megoura, Musca, Pieris, Nilaparvata, Nephotettix, Tetranychus, Trialeurodes, Thysanoptera

10

P.15/18

-35-

or Lepidoptera.

- 38. A composition comprising an essential oil in a gel carrier, said essential oil being obtained from a plant selected from the genera Pelargonium, Cymbopogon, Pimpinella, Myrtus (cretian, Morrocan, organe), Lavandula, Pinus, Melaleuca, Cinnamomum, Apium, Thymus, Hyssopus, Rosemarinus, Cananga, Mentha, Eucalyptus or Vitex for use as a medicament for topical administration.
 - 39. A composition as claimed in claim 38 wherein said gel is as defined in any one of claims 5 to 7.
- 15 40. Use of a gel and an essential oil defined in claims 38 or 39 in the manufacture of a composition as claimed in claim 38 or 39 for the treatment of a human or animal having a parasitic insect infestation.
- 20 41. A composition comprising the alkaloid galanthamine for use as a medicament for topical administration.
- 42. A composition for use as claimed in claim 41 wherein said composition comprises an extract of a plant of the genus Narcissus.
- 43. A composition for use as claimed in claim 41 or 42 wherein said galanthamine or extract is dissolved in an oil-based medium, a water/alcohol based medium or is formulated as a hair conditioner or shampoo or as a gel, dip or pour on treatment.
- 44. A composition as claimed in claim 43 wherein said gel is as defined in any one of claims 5 to 7.

-36-

- A composition as claimed in claim 43 wherein said galanthamine or extract is carried in a vehicle comprising from about 0.1 to about 20% alcohol (v/v).
- 5 A composition as claimed in claim 45 wherein said vehicle comprises about 20% v/v isopropyl alcohol.
- 47. Use of galanthamine or an extract of 10 Narcissus in the manufacture of a composition for treating a human or animal suffering from a parasitic insect infestation.
- A method of treating a human or animal 15 suffering from a parasitic insect infestation which comprises applying to said human or animal a composition as claimed in any one of claims 41 to 46.
- A composition for use as claimed in any one 20 of claims 41 to 46 wherein said parasitic insects are selected from lice, lice eggs, mites, fleas or parasites associated with blowfly strike.
- A composition for use as claimed in claim 49 25 wherein said parasitic insects are selected from head lice (Pediculus humanus capitis, syn. P. capitis), clothing lice (Pediculus humanus humanus syn. P. corporis), pubic lice (Pthirius pubis), biting lice (Bovicula ovis), scab mite (Psoroptes ovis), ear mite 30 (Psoroptes cuniculi), dust mites (primarly of the genus Dermatophagoides), pig mites, cat fleas (Ctenocephalalides felis), dog fleas (C. canis), horse fleas and Lucilia or Chrysomya species.
- 35 51. A method suitable for treating furnishing or clothing to kill parasitic insects which comprises

-37**-**

exposing said furnishings or clothing to a composition of the type defined in any one of claims 41 to 46, 49 and 50.

- 52. A method suitable for treating plants to kill parasitic insects which comprises applying to said plants a composition of the type defined in any one of claims 41 to 46, 49 and 50.
- 53. A method for killing parasitic insects selected from the genera Aphis, Chilo, Dysdercus, Megoura, Musca, Pieris, Nilaparvata, Nephotettix, Tetranychus, Trialeurodes, Thysanoptera and Lepidoptera, by applying the compositions of any one of claims 38 to 46.
- combination of two or more of, the terpenes and terpenoids selected from the group consisting of:

 20 sabinene, sabinene(+), sabinene(-), limonine(D), limonene(L), caryophyllene, myrcene, tepinen-4-ol, p-cymene, borneol, camphor, p-cymene, a-terpineol, camphene, a-pinene, b-pinene, linalool, 1,8-cineol, a/b thujone, camphene, for the preparation of a medicament for treating humans, animals having a parasitic insect infestation suitable for topical administration.
- 55. Use as claimed in claim 54 wherein said terpene or terpenoid is selected from one or more of sabinene, p-cymene, β-pinene, myrcene, limonene and terpinen-4-ol.
- 56. Use as claimed in claim 55 wherein said terpenes/terpenoids are chosen from a combination of sabinene with limonene and/or terpinen-4-ol.

P.18/18

-38-

57. Use of one of the terpenes and terpenoids selected from the group consisting of: sabinene, sabinene(+), sabinene(-), limonene(D), limonene(L), caryophyllene, myrcene, tepinen-4-ol, p-cymene, borneol, camphor, p-cymene, a-terpineol, camphene, a-pinene, b-pinene, linalool, 1,8-cineol, a/b thujone, camphene, at a concentration of about 4% by weight or above for the preparation of a medicament for treating humans, animals having a parasitic insect infestation.

10

5

- 58. The use of claim 57 modified to include one or more further terpene or terpenoid compounds from said group.
- 59. A method suitable for treating furnishing or clothing to kill parasitic insects which comprises exposing said furnishing and clothing to a gel carrier and one or more of the terpenes and terpenoids, as defined in any one of claims 54-58.

20

25

60. A method suitable for treating plants to kill parasitic insects which comprises applying to said plants a gel carrier and one or more of the terpenes, terpenoids as defined in any one of claims 54-58.

: 309380: SIM: LP: LOMOOCS

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER see Notification (Form PCT/ISA/	of Transmittal of International Search Report 220) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/GB 00/01589	25/04/2000	23/04/1999
Applicant		
	`	
WILKINSON; JOHN ALFRED		
according to Article 18. A copy is being		hority and is transmitted to the applicant
This International Search Report consis	ts of a total ofsheets. by a copy of each prior art document cited in this	report.
Basis of the report		
 a. With regard to the language, the language in which it was filed, u 	e international search was carried out on the ba nless otherwise indicated under this item.	sis of the international application in the
the international search Authority (Rule 23.1(b))	was carried out on the basis of a translation of t	he international application furnished to this
 With regard to any nucleotide a was carried out on the basis of the ba	and/or amino acid sequence disclosed in the in the in the sequence listing:	nternational application, the international search
	tional application in written form.	
	ternational application in computer readable for	m.
	to this Authority in written form.	
	to this Authority in computer readble form. ubsequently furnished written sequence listing o	loss not an beyond the disclosure in the
international application	as filed has been furnished.	
the statement that the ir furnished	formation recorded in computer readable form i	s identical to the written sequence listing has been
2. Certain claims were fo	und unsearchable (See Box I).	
3. X Unity of invention is la	cking (see Box II).	
4. With regard to the title,		·
X the text is approved as	submitted by the applicant.	•
the text has been estable	ished by this Authority to read as follows:	
5. With regard to the abstract,		
X the text is approved as s	submitted by the applicant.	
the text has been establ within one month from the	ished, according to Rule 38.2(b), by this Authorine date of mailing of this international search rep	ty as it appears in Box III. The applicant may, port, submit comments to this Authority.
6. The figure of the drawings to be put	blished with the abstract is Figure No.	
as suggested by the app	olicant.	X None of the figures.
because the applicant fa	ailed to suggest a figure.	
because this figure bette	er characterizes the invention.	





Box	Obs rvations where certain laims were found unsearchable (Continuation of item 1 of first sheet)
This I	nternational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. [Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
з. [Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Вх	Il Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This	International Searching Authority found multiple inventions in this international application, as follows:
	see additional sheet
1. [As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. [As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. [As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.: 1-19,33,34,38-57
4. [No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Ren	The additional search fees were accompanied by the applicant's protest. X No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-19, 33 (partly), 34 (partly)

A composition for use in the treatment of a human or animal having a parasitic insect infestation comprising an essential oil obtained from a plant selected from the genera Artemisia, Citrus, Juniperus, Laurus, Myristica, Origanum, Piper or Aloysia in a gel carrier.

Use of a gel and essential oil as defined above in the manufacture of a composition for the treatment of a human or animal having a parasitic oinsect infestation.

A method of treating a human or animal suffering from a parasitic insect infestation by applying a composition as defined hereabove.

2. Claims: 20,21, 29, 30 (partly), 33 - 37 (all partly), 52 (partly)

A composition for use in the treatment of a human or animal having a parasitic insect infestation comprising an essential oil obtained from a plant selected from the genera Artemisia, Citrus, Juniperus, Laurus, Myristica, Origanum, Piper or Aloysia in an aqueous alcoholic vehicle comprising from 0.1% - 20% v/v alcohol with water.

Use of a composition as defined above in the manufacture of a composition for the treatment of a human or animal having a parasitic insect infestation.

Method of treating a human or animal suffering from a parasitic insect infestation by applying the composition defined hereabove.

Method suitable for treating furnishing, clothing or plants to kill parasitic insects by applying the composition defined hereabove.

3. Claims: 22-28, 30 (partly), 31, 32, 33 - 37 (all partly), 52 (partly)

A composition for use in the treatment of a human or animal having a parasitic insect infestation comprising an essential oil obtained from a plant selected from the genera Artemisia, Citrus, Juniperus, Laurus, Myristica, Origanum, Piper or Aloysia in an alcohol/vegetable oil mixture comprising from 0.1% - 20% v/v alcohol.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Use of a composition as defined above in the manufacture of a composition for the treatment of a human or animal having a parasitic insect infestation.

Method of treating a human or animal suffering from a parasitic insect infestation by applying the composition defined hereabove.

Method suitable for treating furnishing, clothing or plants to kill parasitic insects by applying the composition defined hereabove.

4. Claims: 38, 39, 52 (partly)

Composition comprising an essential oil obtained from a plant selected from the genera Petergonium, Cymbopogan, Pimpinella, Myrtus (Cretian, Moroccan, organe), Lavandula, Pinus, Melaleuca, Cinnamomum, Apium, Thymus, Hyssopus, Rosmellus, Cananga, Mentle, Eucalyptus or Vitex in a gel carrier.

Method for treating plants to kill insects by applying this composition.

5. Claims: 40- 51, 52 (partly)

Composition comprising the alkaloid galanthamine for use in the treatment of a human or animal having a parasitic insect infestation.


Use of galanthamine or an extract of Narcissus in the manufacture of a composition for treating a human or animal suffering from a parasitic insect infestation.

Method of treating a human or animal suffering from a parasitic insect infestation by applying the composition defined hereabove.

Method suitable for treating furnishing, clothing or plants to kill parasitic insects by applying the composition defined hereabove.

6. Claims: 53 - 57

Composition comprising a gel carrier and one or more of the terpenes and terpenoids shown to have insecticidal activity for use in treating humans, animals, clothing, furnishing and plants (preferably selected from sabinene, p-cymene, beta-pinene, myrcene, limonene and terpinen-4-ol).



A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A01N65/00 A01N25/04

A01N25/02

A61K35/78

A61K7/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\label{localization} \begin{array}{ll} \mbox{Minimum documentation searched (classification system followed by classification symbols)} \\ \mbox{IPC} \cdot 7 & \mbox{A01N} & \mbox{A61K} \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)


WPI Data, EPO-Internal, PAJ

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CH 688 787 A (LINSIG DIETER ;RICHLI THOMAS (CH)) 31 March 1998 (1998-03-31) column 2, line 4,15-42,60 column 3, line 6-14,18,19,34-37; example 2	1-39, 52-57
Ρ,Χ	WO 00 00213 A (ARBOR VIDA NATURAL PRODUCTS; WOLFF RICKI DE (US)) 6 January 2000 (2000-01-06) cited in the application page 2, line 14-24 page 3, line 3 -page 4, line 28 page 5, line 1 -page 6, line 2; table 1	20-39, 52-57


Y Further documents are listed in the continuation of box C.	χ Patent family members are listed in annex.
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
29 September 2000	/2 5. 10. 00
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Authorized officer Klaver, J



0.00==1===	POCHMENTS CONCIDEDED TO BE DELEVANT	GB 00/01589
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 1998, no. 10, 31 August 1998 (1998-08-31) & JP 10 120519 A (OSAKA SEIYAKU:KK), 12 May 1998 (1998-05-12) abstract	1-37,52
X	EP 0 495 684 A (CLILCO LTD) 22 July 1992 (1992-07-22) cited in the application	1-5,7-9, 11,12, 20-25, 28,33, 34,38, 39,53-57
	see: page 2, line 44-50; page 3, line 48-56; page 4, line 11 - 13; page 7, line 47/48.	
X	US 4 933 371 A (HINK W FREDRIC ET AL) 12 June 1990 (1990-06-12) column 1, line 31-38 column 3, line 63 -column 4, line 19 column 7, line 32-38 column 20, line 9-23	53-57
P,X	WO 99 37148 A (XIMED GROUP PLC ;FRANKLIN LANNY (US)) 29 July 1999 (1999-07-29) see: page 1, par. 4; page 13, par. 1-3.	53-57
P,X	GB 2 341 091 A (ORE-AN LTD) 8 March 2000 (2000-03-08) cited in the application see: page 1, line 11-13; page 2, line 21-23; page 3, line 5.	22-28, 30-39,52
X	WO 96 14046 A (UNIV RAMOT ;ROSENBERG MELVYN (IL)) 17 May 1996 (1996-05-17) page 1, paragraph 2 page 3, paragraph 4; examples 3,7	1-39, 52-57
X	WO 96 37210 A (ROPAPHARM B V I O ;NINKOV DUSAN (NL)) 28 November 1996 (1996-11-28) page 2, line 27-36 page 3, line 6-24; examples 4,6	1-39, 52-57
	-/	



C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.				
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
DATABASE WPI Week 8849, 1988 Derwent Publications Ltd., London, GB; AN 1988-349708 XP002042392 "Gel-type base material for fragrance composition-obtd by mixing nonionic cellulose deriv. with aq. gel." & JP 63 260956 A (LION CORP.), 27 October 1988 (1988-10-27) abstract	1-5,7,8, 10,11			
WO 97 17944 A (AL CHI MI A S R L; CALDERINI GABRIELLA (IT); SCESA CARLA (IT)) 22 May 1997 (1997-05-22) page 1, line 15-27; example 4	1-3,5, 7-9,11, 38,39			
WO 95 23815 A (SPORTS EZE LIMITED; HOLLOWAY GEORGE DOUGLAS JAMES (NZ); MILLER IAN) 8 September 1995 (1995-09-08) examples 7,9	1-3,5,7, 8,38,39, 53			
WO 97 47193 A (WATKINS MAX; VITA EUROP LTD (GB)) 18 December 1997 (1997-12-18) page 2, paragraph 3 page 3, paragraph 5 page 5, paragraph 6; examples 1-4	38,39, 53-57			
GB 2 224 934 A (STUART ANGUS ERSKINE) 23 May 1990 (1990-05-23) the whole document	38,39			
WO 98 22152 A (GUINANE PTY LTD P; CRAWFORD IAN (AU); TEETEEOH RESEARCH GROUP PTY) 28 May 1998 (1998-05-28) page 3, line 1-17 page 4, line 1-19; examples 1-12	38,39			
A. NUMATA ET AL.: "Antifeedants for the larvae of the Yellow Butterfly, Eurema hecabe, in Lycoris radiata" CHEM. PHARM. BULL., vol. 31, no. 6, 1983, pages 2146-2149, XP002148848 page 2149, line 5-19	40-42, 48-52			
US 5 519 017 A (OPITZ KLAUS) 21 May 1996 (1996-05-21) column 4, line 1-41 column 5, line 12-31	40-42, 44,45, 48,49			
	DATABASE WPI Week 8849, 1988 Derwent Publications Ltd., London, GB; AN 1988-349708 XP002042392 "Gel-type base material for fragrance composition-obtd by mixing nonionic cellulose deriv. with aq. gel." & JP 63 260956 A (LION CORP.), 27 October 1988 (1988-10-27) abstract W0 97 17944 A (AL CHI MI A S R L; CALDERINI GABRIELLA (IT); SCESA CARLA (IT)) 22 May 1997 (1997-05-22) page 1, line 15-27; example 4 W0 95 23815 A (SPORTS EZE LIMITED; HOLLOWAY GEORGE DOUGLAS JAMES (NZ); MILLER IAN) 8 September 1995 (1995-09-08) examples 7,9 W0 97 47193 A (WATKINS MAX; VITA EUROP LTD (GB)) 18 December 1997 (1997-12-18) page 2, paragraph 5 page 3, paragraph 5; page 5, paragraph 6; examples 1-4 GB 2 224 934 A (STUART ANGUS ERSKINE) 23 May 1990 (1990-05-23) the whole document W0 98 22152 A (GUINANE PTY LTD P; CRAWFORD IAN (AU); TEETECH RESEARCH GROUP PTY) 28 May 1998 (1998-05-28) page 3, line 1-17 page 4, line 1-19; examples 1-12 A. NUMATA ET AL.: "Antifeedants for the larvae of the Yellow Butterfly, Eurema hecabe, in Lycoris radiata" CHEM. PHARM. BULL., vol. 31, no. 6, 1983, pages 2146-2149, XP002148848 page 2149, line 5-19 US 5 519 017 A (OPITZ KLAUS) 21 May 1996 (1996-05-21) column 4, line 1-41 column 5, line 12-31			



		r GB 00/01589
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 29332 A (LOHMANN THERAPIE SYST LTS; HILLE THOMAS (DE); HOFFMANN HANS RAINER) 26 September 1996 (1996-09-26) page 4, line 1-20	40-42, 44,45, 48,49
X	WO 94 09631 A (GISQUARE TECH BV; ROVESTI GUIDO (IT); SEGALLA GABRIELE (IT); FRATT) 11 May 1994 (1994-05-11) page 6, line 1-20 page 7, line 15-26; examples 5-11	53,54, 56,57
X	DATABASE WPI Section Ch, Week 199226 Derwent Publications Ltd., London, GB; Class A96, AN 1992-211969 XP002148849 & JP 04 139104 A (ARAKAWA CHEM IND LTD), 13 May 1992 (1992-05-13) cited in the application abstract	53-57
X	DATABASE WPI Section Ch, Week 198005 Derwent Publications Ltd., London, GB; Class A97, AN 1980-08537C XP002148850 & JP 54 160739 A (DASUKIN FRANCHISE K), 19 December 1979 (1979-12-19) abstract	53-57
X	US 4 379 168 A (DOTOLO VINCENT) 5 April 1983 (1983-04-05) column 2, line 11-33 column 6, line 66 -column 7, line 4	53-57
X	S. PERRUCCI & G. MACCHIONI: "Structure/activity relationship of some natural monoterpenes as acaricides against Psoroptes cuniculi." J. NATURAL PRODUCTS, vol. 58, no. 8, August 1995 (1995-08), pages 1261-1264, XP000916948 page 1261, column 1, paragraph 2 -column 2, paragraph 1 page 1262, column 1, paragraph 1 -column 2, paragraph 1; table 1	53-57
	-/	



		P GB 00/01589
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	C. REGNAULT-ROGER ET AL.: "Insecticidal effect of essential oils from mediterranean plants upon Acanthoscelides obtectus say (Coleoptera, Bruchidae), a pest of kidney bean." J. CHEM. ECOLOGY, vol. 19, no. 6, 1993, pages 1233-1244, XP000940842 see: 'Discussion' and Table 1.	53-57

n on patent family members

Internal Application No GB 00/01589

				00/01589
Patent document cited in search report	t	Publication date	Patent family member(s)	Publication date
CH 688787	Α	31-03-1998	NONE	
WO 0000213	Α	06-01-2000	AU 4727999 A	17-01-2000
JP 10120519	Α	12-05-1998	NONE	·
EP 0495684	Α	22-07-1992	AU 659625 B AU 1013992 A CA 2059414 A IL 100641 A MX 9200222 A US 5411992 A US 5227163 A ZA 9200342 A	25-05-1995 23-07-1992 19-07-1992 29-12-1994 01-08-1992 02-05-1995 13-07-1993 30-09-1992
US 4933371	Α	12-06-1990	AU 4535785 A BE 902977 A DE 3526911 A FR 2571220 A GB 2163651 A IT 1214659 B JP 61083103 A NL 8502137 A PT 80862 A,B	20-02-1986 27-01-1986 13-03-1986 11-04-1986 05-03-1986 18-01-1990 26-04-1986 17-02-1986 01-08-1985
WO 9937148	Α	29-07-1999	US 5977186 A AU 2340699 A NO 20003607 A	02-11-1999 09-08-1999 13-07-2000
GB 2341091	Α	08-03-2000	NONE	
WO 9614046	Α	17-05-1996	IL 111554 A AU 3768795 A	09-05-1999 31-05-1996
W0 9637210	Α	28-11-1996	AU 708703 B AU 5846096 A BG 102142 A BR 9608841 A CA 2222563 A CN 1190892 A EP 0828502 A HU 9900312 A JP 11505832 T NZ 308661 A	12-08-1999 11-12-1996 29-05-1998 07-12-1999 28-11-1996 19-08-1998 18-03-1998 28-07-1999 25-05-1999 29-07-1999
JP 63260956	Α	27-10-1988	JP 2532090 B	11-09-1996
WO 9717944	Α	22-05-1997	IT VR950092 A	16-05-1997
WO 9523815	Α	08-09-1995	AU 684293 B AU 7009494 A CA 2184838 A EP 0748339 A NZ 267716 A	11-12-1997 18-09-1995 08-09-1995 18-12-1996 24-02-1997
WO 9747193	Α	18-12-1997	AT 195843 T AU 3338297 A BG 103057 A	15-09-2000 07-01-1998 29-10-1999

nfo n on

n on patent family members

International Application No GB 00/01589

Patent document		Publication		Patent family		Publication
cited in search report		date		member(s)		date
WO 9747193	Α		CA	2257840		18-12-1997
			CN	1227465	Α	01-09-1999
			CZ	9804102		16-06-1999
			EP	0869714		14-10-1998
			PL	330475		24-05-1999
			SK	169298	A 	12-07-1999
GB 2224934	Α	23-05-1990	NONE	. 		
WO 9822152	Α	28-05-1998	AU	713618		09-12-1999
			AU	4611497		10-06-1998
			EP	0948362		13-10-1999
			US 	6086904	A 	11-07-2000
US 5519017	Α	21-05-1996	DE	4010079		02-10-1991
			US	5932238		03-08-1999
		•	AT	108657		15-08-1994
			CA	2039197		30-09-1991
			DE	59102210		25-08-1994
			DK Ep	449247		21-11-1994
			ES	0449247 2061094	A T	02-10-1991 01-12-1994
			JP	2055032		23-05-1996
			JP	4221315		11-08-1992
			JP	7068127		26-07-1995
WO 9629332	Α	26-09-1996	DE	19509663		19-09-1996
			AU	707203		08-07-1999
			AU	5108896		08-10-1996
			CA CZ	2215351 9702835		26-09-1996 17-12-1997
			EP	0815112		07-01-1998
			HU	9802234		01-02-1999
			JP	11505519		21-05-1999
			NO	974119		08-09-1997
			NZ	304008		24-09-1998
			PL	322463		02-02-1998
			SK	123597		04-02-1998
			US	5877172		02-03-1999
			ZA	9602140	A 	16-09-1996
WO 9409631	A	11-05-1994	GB	2271929		04-05-1994
			AU	5371694		24-05-1994
			EP	0667743		23-08-1995
			US	5607674	A 	04-03-1997
JP 4139104	Α	13-05-1992	NONE			
JP 54160739	Α	19-12-1979	JP	1343903	С	29-10-1986
			JP	61007830		10-03-1986